|
| Press Releases |
|
 |
|
| Tuesday, March 2, 2021 |
|
|
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong |
| Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Monday, February 22, 2021 |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090 |
| Eisai Co., Ltd. announced that it has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor E7090, which is currently under development as an orally available novel anti-cancer agent. more info >> |
|
|
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy |
| Eisai Co., Ltd. announced today that it has received the 18th Corporate Philanthropy Award (FY 2020) of the Japan Philanthropic Association. The presentation ceremony was held on February 19, 2021 (Friday) at the GakushiKaikan (Chiyoda-ku, Tokyo). more info >> |
|
| Monday, February 15, 2021 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the first presentation of new investigational data from the pivotal Phase 3 CLEAR study (Study 307/KEYNOTE-581) in an oral presentation session (Abstract #269) at the virtual 2021 Genitourinary Cancers Symposium (ASCO GU) and simultaneously published in the New England Journal of Medicine. more info >> |
|
| Wednesday, February 3, 2021 |
|
|
Two Immigrants, One Unique Plan For A Biopharma |
| The American Dream is why the United States is considered the "land of opportunity," and why for centuries immigrants have flocked to our shores seeking their fortunes. Sanjeev Redkar, Ph.D., (India) and Guo-Liang Yu, Ph.D., (China) came to the U.S. in the 1980s. By anyone's reasonable measure, both have achieved the American Dream. However, their dream as scientists remained at arm's length. more info >> |
|
| Monday, February 1, 2021 |
|
|
Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea |
| Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide"). This is the first launch of Equfina in the Asian region excluding Japan. more info >> |
|
| Tuesday, January 26, 2021 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time |
| Eisai Co., Ltd. announced that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
| Tuesday, January 12, 2021 |
|
|
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium |
| Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021. more info >> |
|
| Friday, December 18, 2020 |
|
|
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan |
| Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
| Thursday, December 17, 2020 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR |
| These positive results were observed in the mismatch repair proficient (pMMR) subgroup and the intention-to-treat (ITT) study population, which includes both patients with endometrial carcinoma that is pMMR as well as patients whose disease is microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Cornerstone Robotics Completes the World's First Clinical Validation of Autonomous Surgery Performed by Robot-Assisted Surgery 
Aug 6, 2025 19:21 HKT/SGT
|
|
|
" title="Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept
">
Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept
Aug 6, 2025 19:40 JST
|
|
|
Dream Incubator and DENSO Launch Demonstration Project for Digital Platform Development for Mobility Circular Economy and Integrated Manufacturing for India
Aug 6, 2025 18:54 JST
|
|
|
International Land Alliance Brings Baja to Buyers with Live Zoom Webinar Experience
Aug 6, 2025 17:32 HKT/SGT
|
|
|
Luxren Capital Rolls Out High-Performance Mobile Trading App for Global Users
Aug 6, 2025 17:00 HKT/SGT
|
|
|
MyFintech Week 2025 Highlights Transformative Forces in Finance
Aug 6, 2025 17:00 HKT/SGT
|
|
|
Robot Boom in HK: Shoucheng Holdings at the Forefront
Aug 6, 2025 16:35 HKT/SGT
|
|
|
iFex Capital Launches Major Mobile Trading App Overhaul to Meet Surging Demand
Aug 6, 2025 16:00 HKT/SGT
|
|
|
35th Food Expo opens next week five theme days kick off premium lifestyle journey
Aug 6, 2025 15:05 HKT/SGT
|
|
|
AITO launches EV Road Tour from Chongqing to Jakarta
Aug 6, 2025 14:22 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million
Aug 6, 2025 13:20 HKT/SGT
|
|
|
University of Cyberjaya Welcomes Education Reforms under RMK13: A Bold Step Toward Future-Ready Talent and Inclusive Innovation
Aug 6, 2025 12:27 HKT/SGT
|
|
|
Fujitsu's CHRO Roundtable Report 2025 highlights data-driven HRBP practices for human capital management
Aug 6, 2025 11:00 JST
|
|
|
TruMerit Launches Global Credential for First-Level, General Nurses
Aug 6, 2025 09:00 HKT/SGT
|
|
|
MHI Selected to Enter Next Stage Procurement Process for Australia's New General-Purpose Frigates
Aug 5, 2025 22:02 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
